Climb Bio Extends Cash Runway to 2028, Sets Key Data Catalysts for H2 2026
CLYM has more than doubled off its 52-week low of $1.54.
Summary
Climb Bio reported Q2 2026 results and provided a pipeline update that extends its cash runway into the second half of 2028, removing near-term financing risk. The company announced a September 3 R&D Spotlight for initial Phase 1 CLYM116 data and expects multiple budoprutug readouts in Q4 2026 across pMN, ITP, and SLE. This follows positive Phase 1b ITP data in June and the recent $100M ATM facility. The extended runway and concentrated catalyst timeline strengthen the setup into year-end.
At the time of this announcement, CLYM was trading at $12.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $714.1M. The 52-week trading range was $1.54 to $14.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.